GlassScriptPhysician profile
Michael R Denardis
NPI 1245378033
$2,563.06
in general payments reported to CMS, 2019-2025
30 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $152 · 2021: $447 · 2022: $704 · 2023: $494 · 2024: $368 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optumhealth Care Solutions, LLC | $341.06 | 2024-2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Abbvie INC. | $332.31 | 2019-2023 | Orilissa, Lo Loestrin Fe, Oriahnn |
| Hologic Sales and Service, LLC | $247.75 | 2019-2024 | Novasure, Coolseal Generator, Omni Hysteroscope |
| Mayne Pharma Commercial LLC | $210.22 | 2021-2022 | |
| Exeltis, USA INC. | $174.65 | 2020-2025 | Slynd, Nuvessa, Nuvessa |
| Myovant Sciences INC. | $165.15 | 2021-2022 | |
| Coopersurgical, INC. | $119.95 | 2021-2022 | |
| Agile Therapeutics, INC. | $107.87 | 2021-2023 | Twirla |
| Shield Therapeutics INC | $101.87 | 2022-2025 | |
| Astellas Pharma US INC | $99.71 | 2023-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $73.79 | 2019-2022 | |
| Pfizer INC. | $70.16 | 2022-2025 | |
| Scynexis, INC. | $59.13 | 2022 | |
| Momentis Surgical INC. | $57.00 | 2022 | |
| Avion Pharmaceuticals | $52.74 | 2022-2023 | Balcoltra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $48.25 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $46.03 | 2023 | Myfembree |
| Organon LLC | $44.59 | 2022-2023 | Nexplanon |
| Millicent US INC | $40.43 | 2020-2025 | Femlyv |
| Biogen, INC. | $23.49 | 2025 | Zurzuvae |
| Medtronic, INC. | $23.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.08 | 2021 | |
| Exact Sciences Corporation | $19.00 | 2023 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $18.37 | 2021 | |
| Meditrina | $15.65 | 2021 | |
| Minerva Surgical, INC | $14.89 | 2025 | |
| Merck Sharp & Dohme LLC | $14.62 | 2019 | |
| Allergan, INC. | $11.19 | 2019 | |
| Aspira Women'S Health INC | $10.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Denardis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.